Analyst Price Target is $12.33
▲ +166.38% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Roivant Sciences in the last 3 months. The average price target is $12.33, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 166.38% upside from the last price of $4.63.
Current Consensus is
The current consensus among 8 polled investment analysts is to buy stock in Roivant Sciences.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.